BUSINESSAug 5 · 10:57 UTCCNBC TOP

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly reported quarterly results that exceeded expectations, leading to an upward revision of its 2026 revenue forecast. The company now anticipates revenue between $85 billion and $87 billion for 2026, driven by strong sales of Zepbound and Mounjaro.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Eli LillyorganizationZepboundtopicMounjarotopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSAug 5 · 11:17 UTC
Lilly’s revenue soars 48%, driven by demand for its GLP-1s
BUSINESSJul 22 · 12:10 UTC
GE Vernova raised its 2026 revenue forecast after strong earnings beat expectations
BUSINESSMay 26 · 11:50 UTC
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
BUSINESSJul 28 · 11:20 UTC
Coca-Cola posted stronger-than-expected earnings and raised its full-year profit forecast